Cardinal Capital Management Lowers stake in BARD C R INC COM (BCR)

BARD C R INC COM (BCR) : Cardinal Capital Management reduced its stake in BARD C R INC COM by 0.08% during the most recent quarter end. The investment management company now holds a total of 23,339 shares of BARD C R INC COM which is valued at $4,836,541 after selling 19 shares in BARD C R INC COM , the firm said in a disclosure report filed with the SEC on Apr 21, 2016.BARD C R INC COM makes up approximately 1.99% of Cardinal Capital Management’s portfolio.

BARD C R INC COM opened for trading at $206.52 and hit $211.48 on the upside on Wednesday, eventually ending the session at $210.19, with a gain of 2.27% or 4.66 points. The heightened volatility saw the trading volume jump to 8,42,602 shares. Company has a market cap of $15,498 M.

Other Hedge Funds, Including , Eagle Ridge Investment Management reduced its stake in BCR by selling 24 shares or 0.09% in the most recent quarter. The Hedge Fund company now holds 25,645 shares of BCR which is valued at $5,314,413. BARD C R INC COM makes up approx 1.22% of Eagle Ridge Investment Management’s portfolio. Dorsey Wright Associates added BCR to its portfolio by purchasing 2,319 company shares during the most recent quarter which is valued at $470,502. BARD C R INC COM makes up approx 0.25% of Dorsey Wright Associates’s portfolio.Creative Planning boosted its stake in BCR in the latest quarter, The investment management firm added 20 additional shares and now holds a total of 3,275 shares of BARD C R INC COM which is valued at $664,465. BARD C R INC COM makes up approx 0.01% of Creative Planning’s portfolio.

On the company’s financial health, BARD C R INC COM reported $2.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $2.17. The company had revenue of $873.50 million for the quarter, compared to analysts expectations of $847.53 million. The company’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.10 EPS.

Many Wall Street Analysts have commented on BARD C R INC COM. BARD C R INC COM was Initiated by Nomura to “Neutral” on Mar 17, 2016.

C. R. Bard Inc. (Bard) and its subsidiaries are engaged in the design manufacture packaging distribution and sale of medical surgical diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular urology oncology and surgical specialty. The Company also has a product group of other products. The Company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products fecal and urinary continence products urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs in addition to hemostats and surgical sealants.

Leave a Reply

BARD C R INC COM - Is it time to Sell?

Top Brokerage Firms are advising their investors on BARD C R INC COM. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.